Dr. Atkinson Discusses BRAF-Mutant Metastatic Melanoma

Victoria Atkinson, MD
Published Online: Friday, Dec 22, 2017



Victoria Atkinson, MD, medical oncologist, Princess Alexandra Hospital, University of Queensland, discusses the treatment landscape for patients with BRAF-mutant metastatic melanoma.

We have come a long way in a short period of time, says Atkinson. If a patient has BRAF-mutant melanoma, they can be treated with targeted therapy and immunotherapy. The median overall survival (OS) with immunotherapy is 38 months and the OS with targeted therapy is 25.8 months.

According to Atkinson, there is enthusiasm from clinicians to look for better checkpoints inhibitors to have long-term disease control and cure.
 


Victoria Atkinson, MD, medical oncologist, Princess Alexandra Hospital, University of Queensland, discusses the treatment landscape for patients with BRAF-mutant metastatic melanoma.

We have come a long way in a short period of time, says Atkinson. If a patient has BRAF-mutant melanoma, they can be treated with targeted therapy and immunotherapy. The median overall survival (OS) with immunotherapy is 38 months and the OS with targeted therapy is 25.8 months.

According to Atkinson, there is enthusiasm from clinicians to look for better checkpoints inhibitors to have long-term disease control and cure.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Community Practice Connections™: 13th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®Apr 28, 20182.0
Publication Bottom Border
Border Publication
x